Lund

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with … Recruiting
  2023-510369-92-00 4 2025-01-28 Mixed Dyslipidemia
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated gl … Recruiting
  2023-506998-35-00 5 2025-01-08 Glioblastoma
• Vaccination in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the immunogenicity of herpes-zoster … Recruiting
  2023-506230-71-01 6 2024-12-17 inflammatory rheumatic diseases (IRD): rheumatoid arthritis (RA), SLE,
• Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial ( … Recruiting
  2023-508398-10-00 6 2024-12-12 ANCA-associated vasculitis
• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting
  2023-505232-36-00 5 2024-11-15 Essential thrombocythemia
• Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting
  2023-509994-22-00 5 2024-11-15 cutaneous malignant melanoma
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• HYPER-trial Hyperemic mYocardial Perfusion by adEnosine at diffeRent doses Recruiting
  2023-505248-20-00 6 2024-10-14 Chronic coronary syndrome
• VEX-AZA: Treating VEXAS Syndrome with Azacitidine. A Single-Arm, Multicenter Phase II Study on the Efficacy and Safety of Azacitidine in Pat … Recruiting
  2024-510715-30-00 4 2024-09-26 VEXAS
• The One-Month DAPT with Ticagrelor In CABG PatieNts Trial (ODIN) Recruiting
  2023-506613-22-00 5 2024-09-25 coronary artery disease
• Improved Recovery by Iron following Surgery with blood loss, a double-blind multi-centre randomized controlled phase III drug trial (the IRI … Recruiting
  2022-502776-22-00 5 2024-09-05 Anemia
• PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH INTEGRATION OF … Recruiting
  2023-510415-19-00 4 2024-08-28 Acute Myeloid Leukemia
• First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCR … Recruiting
  2023-507486-26-00 1 2024-08-20 Advanced metastatic castration-resistant prostate cancer with prostate
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• Adjuvant therapy in high risk adrenocortical carcinoma (ADIUVO-2) Recruiting
  2022-500013-32-01 5 2024-07-05 Adrenocortical carcinoma
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma Recruiting
  2022-501993-21-00 4 2024-06-20 Dedifferentiated Liposarcoma
• COMeBAC- COMparison between Bensypenicillin And Cloxacillin treatment in PSSA Recruiting
  2023-506860-15-00 6 2024-06-11 Staphylococcus aureus bacteraemia
• A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared … Recruiting
  2023-508156-20-00 5 2024-06-10 Uveal Melanoma Liver Metastases
• Safety and diagnostic performance of uPAR PET imaging in localised, untreated prostate cancer. Recruiting
  2023-507111-35-00 9 2024-06-03 Prostate Cancer
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa … Recruiting
  2023-503208-94-00 6 2024-04-04 Prostate cancer
• SGLT2 inhibitor TrEatment iN patients awaiting cOronary arTery bYpass surgery to reduce Post-opErative atrial fibrillation and kidney injury … Recruiting
  2023-505375-75-00 5 2024-04-04 Onset of Atrial Fibrillation and Acute Kidney Injury after coronary ar
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia

Showing 97–120 of 308 trials